Home Page

Gene Solutions conducts therapeutic drug discovery research for Central Nervous System (CNS) diseases, utilizing its proprietary mitochondrial genomic targets. The company’s primary CNS indications of interest are Alzheimer’s, Parkinson’s and Schizophrenia. NCE discovery research is conducted at the company’s two locations in the USA and UK, while company-developed assays are executed with leading academic collaboration partners. Adding to a comprehensive and unparalleled approach, the company’s unique biomarkers have utility in clinical patient screening and data generation, as well as blood-based companion diagnostics. We partner with pharmaceutical and biotechnology companies to bring novel and vital cures to large segments of our population. We invite you to build upon our cutting-edge research to advance the treatment of devastating diseases affecting large segments of our global population.